| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q3 | Oct 21, 2025 | ClearBridge Mid Cap Growth Strategy | - | - | ATS, QXO | Artificial Intelligence, Biotechnology, healthcare, Industrial Automation, Mid Caps | The fund outperformed through strong stock selection in healthcare and consumer staples, aided by biotech names like Argenx and Alnylam. Managers added positions in Bio-Techne and QXO to capture growth in diagnostics and industrial automation. They remain constructive on mid caps as rate cuts and improving sentiment support selective growth investing. | RBLX |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| No pitches found. | |||||||||
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||